US pharma company raises vaccine hopes but more trials are vital, say experts
Promising details were released this week about Moderna’s Covid-19 vaccine but it remains in the early stages of development
Hopeful news about a Covid-19 vaccine developed by US government researchers and Moderna Inc has buoyed expectations – and markets – on the potential for a preventive measure against a global pandemic that has killed more than half a million people and upended daily life.
Moderna first announced its vaccine, backed by the National Institute of Allergy and Infectious Diseases, prompted an immune response in 45 adults in May.
On Tuesday, it published.
